Ducentis operates as a virtual company, unencumbered by building leases or physical assets, and led by an experienced team with extensive drug discovery and development expertise. Our operational model ensures that investment is focused on securing a data package supporting IP protection, safety, tractable manufacturing options and strong evidence of efficacy in pre-clinical and clinical models.
Dr Philip Huxley
CEO and founder
Read chemistry at the University of Aberdeen and obtained a PhD in theoretical chemistry at the University of Sussex. Philip has a strong track record of innovation and delivery of drug development programmes with 30+ years of drug discovery and development experience at Novartis, British Biotech, Avidex, Galapagos and Bicycle Therapeutics. Philip has played pivotal roles in progressing novel, successful projects from conception to delivery of clinical candidates. He is a named inventor on numerous patents, including four phase II clinical candidates: Todestat, Rhudex, GLP0259 and BT5528.
Dr Rebecca Ashfield
CSO and founder
Has a BA and DPhil from the University of Oxford, and 20+ years of pre-clinical and clinical experience developing biologic therapies targeting autoimmunity, infectious diseases and cancer. Following a career in academia Rebecca worked at Immunocore (formerly Avidex) developing immuno-oncology therapies and the Jenner Institute (University of Oxford) developing vaccines. In 2018 Rebecca authored a grant application which secured £65M funding for the Vaccines Manufacturing and Innovation Centre (VMIC) in Harwell Oxfordshire, and in 2020 was co-opted from Ducentis to help outsource manufacturing of the Oxford SARS-CoV-2 vaccine.